One of our special interests is the rational discovery of protein-protein interaction (ppi) modulators. Indeed, it is considered to be, if not impossible, highly challenging. There are very few reported successes, where the first-in-class small molecule ppi modulators would had been identified via virtual screening, from which we were the very first ones - and now we have further successes, seven in total and increasing. Note that we have not only succeeded with blockers but also with identification of binding enhancers,
How about finding a new way to treat diseases? Quite often the homeostasis of our cells is disturbed when competitively acting drugs are employed - This leads into natural response where cells are producing more of the target protein, thus, collapsing the therapeutic effect of pharmaceutical agent. If drug would only interfere the consequent effect, not the binding of the natural ligand, the homeostasis of cell would be maintained, but still the disease would be treated. Again our startegy in blocking of protein-protein interactions would be the perfect solution.
Do you have an interesting case? We would love to hear it, and collaborate with you!!!! It is as easy as A-B-C-D-E-mail: email@example.com.
Head of the Laboratory
Professor of Medicinal Chemistry (Institute of Biomedicine, UTu)
Adjunct Professor in Biochemistry (Department of Biochemistry, UTu)
Head of the Ligand Discovery Unit/Commercial Project Coordinator
Academy of Finland Post-doctoral Researcher
Research interests: Computer-aided Drug Discovery, Virtual Screening
Post-doctoral Researcher (from 8/2019)(Funded by Academy of Finland)
Research interests: Molecular simulations, Enzyme engineering
University of JyväskyläMetabolism, Software Development
University of Turku; Method Development, Virtual Screening
University of Turku; Virtual Screening and Work-flow Development
University of Turku; Software Development
Find us at some address at those places or hit us with a message!